Prevalence of abnormal glucose tolerance following a transient ischemic attack or ischemic stroke

Archives of Internal Medicine

Volumn 165, Issue 2, 2005, Pages 227-233

  Kernan, Walter N ^a   Viscoli, Catherine M ^a   Inzucchi, Silvia E ^a   Brass, Lawrence M ^a,b   Bravata, Dawn M ^a,b   Shulman, Gerald I ^a,c   McVeety, James C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b West Haven   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CORRELATION ANALYSIS; DIABETES MELLITUS; DIABETIC GLUCOSE TOLERANCE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; WAIST CIRCUMFERENCE;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; ISCHEMIC ATTACK, TRANSIENT; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PREVALENCE; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION;

EID: 12444268259     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.165.2.227     Document Type: Article

References (45)

1. Smith NL, Barzilay JI, Shatter D, et al. Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly. Arch Intern Med. 2002;162:209-216.
2. DECODE Study Group; the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality; comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397-404.
3. Meigs JB, Nathan DM, Wilson PWF, Cupples LA, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. Ann Intern Med. 1998;128:524-533.
4. Eckel RH, Wassef M, Chait A, et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation. 2002;105:e138-e143.
5. Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Horwitz RI. Insulin resistance and risk for stroke. Neurology. 2002;59:809-815.
6. de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population. JAMA. 2001;285: 2109-2113.
7. Weyer C, Bogardus C, Tataranni PA, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001; 24:89-94.
8. Hier DB, Foulkes MA, Swiontoniowski M, et al. Stroke recurrence within 2 years after ischemic infarction. Stroke. 1991;22:155-161.
9. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke. 2001;32:280-299.
10. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a Statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134-1146.
11. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. JAMA. 2002; 287:2570-2581.
12. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with leisure intervention or metformin. N Engl J Med. 2002;346:393-403.
13. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
14. Buchanan TA, Xiang AH, Peters RK, et al. Protection from type 2 diabetes persists in the TRIPOD cohort eight months after stopping troglitazone [abstract]. Diabetes. 2002;50(suppl 2):A81.
15. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes: the STOP-NIDDM randomized trial. Lancet. 2002; 359:2072-2077.
16. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA. 2003;290:486-494.
17. Bronnum-Hansen H, Davidsen M, Thorvaldsen P; Danish MONICA Study Group. Long-term survival and cause of death after stroke. Stroke. 2001;32:2131-2136.
18. Kernan WN, Viscoli CM, Brass LM, et al. The stroke prognosis instrument II (SPI-II): a clinical prediction instrument for patients with transient ischemic and non-disabling ischemic stroke. Stroke. 2000;31:456-462.
19. Petty GW, Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota 1975-1989. Neurology. 1998;50:208-216.
20. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. Estrogen replacement after ischemic stroke: report of the Women's Estrogen for Stroke Trial (WEST). N Engl J Med. 2001;345:1243-1249.
21. Vernino S, Brown RD, Sejvar JJ, Sicks JD, Petty GW, O'Fallon M. Cause-specific mortality after cerebral infarction: a population-based study. Stroke. 2003; 34:1828-1832.
22. Kernan WN, Viscoli CM, Inzucchi SE, et al. Insulin resistance among patients with ischemic stroke and TIA [abstract]. Stroke. 2002;33:389.
23. Kernan WN, Inzucchi SE, Viscoli CM, et al. Pioglitazone improves insulin sensitivity among non-diabetic patients with a recent TIA or ischemic stroke. Stroke. 2003;34:1431-1436.
24. Tonino RP. Effect of physical training on the insulin resistance of aging. Am J Physiol. 1989;256:E352-E356.
25. McDowell I, Newell C. Measuring Health. New York, NY: Oxford University Press; 1996.
26. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care. 1999;22:1462-1470.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412-419.
28. Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med. 1998;158:1855-1867.
29. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-2497.
30. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26(suppl 1):S5-S20.
31. Kiers L, Davis SM, Larkins R, et al. Stroke typography and outcome in relation to hyperglycemia and diabetes. J Neurol Neurosurg Psychiatry. 1992;55:263-270.
32. Lee T-H, Ryu S-J, Chen S-T. The prognostic value of blood glucose in patients with acute stroke. J Formosan Med Assoc. 1991;90:465-470.
33. Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359:2140-2144.
34. Kagansky N, Knobler H. The role of hyperglycemia in acute stroke. Arch Neurol. 2001;58:1209-1212.
35. Scott JF, Robinson GM, French JM, O'Connell JE, Alberti KGMM, Gray CS. Prevalence of admission hyperglycemia across clinical subtypes of acute stroke. Lancet. 1999;353:376-377.
36. Baird TA, Parsons MW, Phanh T, et al. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke. 2003;34:2208-2214.
37. Kawai N, Keep RF, Betz AL. Hyperglycemia and the vascular effects of cerebral ischemia. Stroke. 1997;28:149-154.
38. Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the MINDS rt-PA Stroke Trial. Neurology. 2002;59:669-674.
39. Auer RN. Insulin, blood glucose levels, and ischemic brain damage. Neurology. 1998;51(suppl3):S39-S43.
40. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemic and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke. 2001;32:2426-2432.
41. Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? results of a long-term follow up study. BMJ. 1997;314:1303-1306.
42. Bruno A, Biller J, Adams HP, et al. Acute blood glucose level and outcome from ischemic stroke. Neurology. 1999;52:280-284.
43. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-1367.
44. Haffner SM. Glucose-tolerance testing in acute myocardial infarction. Lancet. 2002; 359:2127-2128.
45. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27(suppl 1):S5-S10.